Document is current
Any future updates will be listed below
-
Authors
Soragni, Alice https://orcid.org/0000-0002-6634-2885
Knudsen, Erik S. https://orcid.org/0000-0002-5130-5969
O’Connor, Thomas N.
Tognon, Cristina E.
Tyner, Jeffrey W. https://orcid.org/0000-0002-2133-0960
Gini, Beatrice
Kim, Donghwa
Bivona, Trever G. https://orcid.org/0000-0001-5734-4128
Zang, Xingxing https://orcid.org/0000-0001-5380-1942
Witkiewicz, Agnieszka K.
Goodrich, David W.
Jiang, Dadi https://orcid.org/0000-0002-0935-3908
Gammon, Seth T.
Willey, Christopher D.
Boutros, Paul C. https://orcid.org/0000-0003-0553-7520
Sandulache, Vlad C.
Osman, Abdullah A.
Myers, Jeffrey N. https://orcid.org/0000-0003-4767-3408
Mehla, Kamiya
Singh, Pankaj K. https://orcid.org/0000-0001-8903-0131
Chan, Keith S.
Gao, Hongbo
Marathe, Himangi
,
- License Information
-
More Information
Article History
Accepted: 14 April 2025
First Online: 3 June 2025
Change Date: 13 June 2025
Change Type: Update
Change Details: In the version of the article initially published, the Fig. 1 legend inadvertently omitted to state that the figure is adapted from Laisné, M., Lupien, M. & Vallot, C. Epigenomic heterogeneity as a source of tumour evolution. Nat. Rev. Cancer 25, 7–26 (2025). This has now been corrected in the HTML and PDF versions of the article.
Competing interests
: The authors declare no direct competing interests. For full disclosure, C.D.W. has received research funding from Varian Medical Systems, AACR-Novocure and OMS Foundation, clinical trial support from MuReva and Tactile Medical, and consultancy/honoraria from LifeNet Health, Guidepoint Global and EMD Serono; A.S. sits on the Board of the Society for Functional Precision Medicine; P.C.B. sits on the Scientific Advisory Boards of Intersect Diagnostics Inc., BioSymetrics Inc. and previously sat on the board of Sage Bionetworks; E.S.K. has sponsored research funded by Blueprint Medicines and Bristol Myers Squibb and is a member of the Cancer Cell Cyclse–LLC consulting enterprise; A.K.W. has sponsored research funded by Blueprint Medicines and Bristol Myers Squibb; C.E.T. has received funding from AstraZeneca; J.W.T. has received research support from Acerta, Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Kronos, Meryx, Petra, Schrodinger, Seattle Genetics, Syros, Takeda and Tolero and serves on the advisory board for Recludix Pharm, AmMax Bio and Ellipses Pharma; V.C.S. is a consultant for and equity holder in Femtovox Inc.
